Navigation Links
Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
Date:9/15/2008

CAMBRIDGE, Mass., Sept. 15 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that it has met its second milestone in its option agreement with the Novartis Option Fund and will move on to the next phase to validate targets for inflammatory bowel disease (IBD) using Cequent's proprietary TransKingdom RNA interference [tkRNAi(TM)] technology in animal models. Specific payment terms and targets were not disclosed.

"IBD is actually a spectrum of diseases, and the power of RNAi is that you could potentially design therapeutics specifically to target the individual forms of the disease," said Cequent President and CEO, Peter Parker. "When we started the Novartis program, we were evaluating eight targets simultaneously as potential therapeutics for inflammatory bowel disease. Our milestone goal, which we accomplished, was to winnow the targets down to three that we will further validate in in vivo animal trials before Cequent selects the single target to be the subject of the Option agreement. We believe our success with this work, along with progress in our other development programs for Familial Polyposis (FAP) and Human Papilloma Virus (HPV), demonstrate the potential of our tkRNAi technology to become an important tool to better understand, and ultimately, to treat many devastating diseases."

Said Steven Tregay, PhD, a managing director of Novartis Option Fund, "We are impressed with both the quality and speed of the work that Cequent is doing on the IBD program -- as well as the potential of their tkRNAi platform. Creating compounds to address eight targets and completing in vitro screening in only nine months would have been virtually impossible with traditional small-molecule-based drug discovery technologies. We're pleased to release the milestone payment to Cequent, and look forward to our continued relationship both as venture
'/>"/>

SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
2. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
3. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
4. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
5. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
6. VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16
7. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
8. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
9. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
10. Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
11. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...chanised blue dye test alternative is helping br...ance one step closer for pharma-companies. It is a...ne developed by Sepha for use with blister packs...l and global pharma-companies such as Sanofi-Aveni...nd productivity improvements on the packaging line...
(Date:11/25/2009)...ssador to Speak at Economic Club of Canada , ...er 25, 2009 -- Ambassador to Speak at Economic Clu...bassador for International Investment, and Chairma...a biography of David Appia go to www.investinfran...e to meet with press to discuss recent pro-busines...
(Date:11/25/2009)...ire/--Reportlinker.comannouncesthatanewmarketresea...ioethanolMarketAnalysisandForecaststo2013 ,, ...anol-Market-Analysis-and-Forecasts-to-2013.html ,...013 ,, Summary ,, Thereportprovidesdetaile...dtheBrazilbioethanolmarketinparticular.Italsohelps...
(Date:11/24/2009)...ssador to also Visit Detroit , ... Appia, French Ambassador for International Invest... Agency, , , , ,What: Ambassador Appia is availab...ss initiatives adopted by France to further develo... innovation and development., , ,When: Available f...
Breaking Biology Technology:Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 2Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 3French Ambassador for International Investment to Visit Toronto December 11 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9
...l transduction research and drug screening ,...ng Systems, Inc. , , Stratagene has successful...,human MEK1 WT and a constitutively active mutant...sion and purification system.,These MEKs, produc...as MEKs,produced in E. coli are significantly de...
...additives unnecessary , , Kirk B. Nielson ... Systems, Inc. , , This article describes the ...DNA polymerase for minimizing PCR cold start misma...ed extension reactions result in the synthesis of,...m of mismatched extension,reactions may be allev...
...vailable for Robocycler 96 temperature,cyclers...Steege ,Jason Capodanno Michael Rahilly ,Stra...tion of the Hot Top Assembly for RoboCycler , ...ning oil-free,PCR amplifications. Each Hot Top A...th a software upgrade card, which provides more ac...
Other Biology Technology:Production of Full-Length, Biologically Active MEK1WT and MEK1CA 2Production of Full-Length, Biologically Active MEK1WT and MEK1CA 3Production of Full-Length, Biologically Active MEK1WT and MEK1CA 4Production of Full-Length, Biologically Active MEK1WT and MEK1CA 5Pfu DNA Polymerase as a Hot Start Alternative 2Pfu DNA Polymerase as a Hot Start Alternative 3Pfu DNA Polymerase as a Hot Start Alternative 4Pfu DNA Polymerase as a Hot Start Alternative 5Pfu DNA Polymerase as a Hot Start Alternative 6Pfu DNA Polymerase as a Hot Start Alternative 7Pfu DNA Polymerase as a Hot Start Alternative 8Pfu DNA Polymerase as a Hot Start Alternative 9Oil-Free PCR Using the Hot Top Assembly 2Oil-Free PCR Using the Hot Top Assembly 3Oil-Free PCR Using the Hot Top Assembly 4Oil-Free PCR Using the Hot Top Assembly 5Oil-Free PCR Using the Hot Top Assembly 6Oil-Free PCR Using the Hot Top Assembly 7
(Date:11/24/2009)...es from collapsing have been true life-savers. But...ed -- once the arteries are strengthened, they bec... but to leave them in place. , Prof. Meital Zilb...dical Engineering has developed a new patent-pendi... needed, then dissolves. , "Our new composite fi...
(Date:11/24/2009)...rets of the earth,s history locked in its icy dept... information on the environments that have been se...ow, a team of researchers from nine institutions ... million dollars by the National Science Foundatio...ly. These scientists will drill through the West A...
(Date:11/23/2009)...ence that the "synergistic" effect of early-life e...and indoor endotoxin causes more harm to developin... Environmental health scientists at the Universit...n that children exposed to both high levels of tra... early life are six times more likely to experienc...
Breaking Biology News(10 mins):A coating for life 2LSU gets to the bottom of things -- in Antarctica 2Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Gene Network Sciences Announces Cancer Collaboration with University of Connecticut Health Centers Neag Comprehensive Cancer Center 47744 1Gene Network Sciences Announces Cancer Collaboration with University of Connecticut Health Centers Neag Comprehensive Cancer Center 47744 2Gene Network Sciences Announces Cancer Collaboration with University of Connecticut Health Centers Neag Comprehensive Cancer Center 47744 3Audi Teamed Up With Star Quarterback Tom Brady and Celebrities to Support People With Intellectual Disabilities 47742 1Audi Teamed Up With Star Quarterback Tom Brady and Celebrities to Support People With Intellectual Disabilities 47742 2Audi Teamed Up With Star Quarterback Tom Brady and Celebrities to Support People With Intellectual Disabilities 47742 3NYSE Amex LLC Accepts Plan of Compliance of The Quantum Group Inc 47740 1NYSE Amex LLC Accepts Plan of Compliance of The Quantum Group Inc 47740 2NYSE Amex LLC Accepts Plan of Compliance of The Quantum Group Inc 47740 3
... Institute have identified a molecular interaction...reast cancer, and suggest that attacking this targ..., In the January issue of Cancer Cell, a team led ...Dana-Farber report that the interaction of a certa... control flaw is seen in about 10 percent of breas...
... have discovered that butterflies experience a gre...ails of their findings appear in the March issue o...ty for Biochemistry and Molecular Biology journal....rfly is one on nature,s great mysteries," says Wil...iversity in Portland. "Powerful chemical mediator...
...tify caregiver burden and the widower effect, rese...ospitalization of a spouse can harm the wellbeing ... to that partner,s death. This risk also varies wi...n the Feb. 16 New England Journal of Medicine. "Ou...fashion that the health of one person is related t...
Other Biology News:New cellular flaw found in some virulent breast cancers 2New cellular flaw found in some virulent breast cancers 3Butterflies lose body fat during metamorphosis 2Spousal illness can trigger partner death 2Spousal illness can trigger partner death 3Spousal illness can trigger partner death 4
Porcine Galanin , 3-[125I]iodotyrosyl26 Conjugated/Tagged from GE Healthcare, formerly Amersham Biosciences
Terrific Broth from GE Healthcare, formerly Amersham Biosciences
Rabbit Anti-CRIPT Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Mouse Anti-Human VEGF R3 / Flt-4 Monoclonal Antibody, Phycoerythrin Conjugated, Clone 54733 from R&D Systems
Biology Products: